TY - JOUR
T1 - Antibodies to serotype 9V exhibit novel serogroup cross-reactivity following infant pneumococcal immunization
AU - Licciardi, Paul
AU - Balloch, Anne
AU - Russell, Fiona
AU - MULHOLLAND, Edward (Kim)
AU - Tang, Mimi
PY - 2010/5/14
Y1 - 2010/5/14
N2 - Cross-reactivity within the pneumococcal immune response was examined in this study. Significant cross-reactivity between serotypes 9V, 15B and 19A was identified in infant post-immunization serum that could not be effectively titrated during specific IgG measurements. Pre-absorption using serotype 9V inhibited this cross-reactivity and normalized titratability in the WHO ELISA for serotypes 15B and 19A. However, this did not affect functional avid IgG and was associated with fewer pneumococcal conjugate vaccine (PCV) doses, suggesting that cross-reactive antibodies were of low avidity. The results in this study have important implications for assessment of vaccine immunogenicity.
AB - Cross-reactivity within the pneumococcal immune response was examined in this study. Significant cross-reactivity between serotypes 9V, 15B and 19A was identified in infant post-immunization serum that could not be effectively titrated during specific IgG measurements. Pre-absorption using serotype 9V inhibited this cross-reactivity and normalized titratability in the WHO ELISA for serotypes 15B and 19A. However, this did not affect functional avid IgG and was associated with fewer pneumococcal conjugate vaccine (PCV) doses, suggesting that cross-reactive antibodies were of low avidity. The results in this study have important implications for assessment of vaccine immunogenicity.
U2 - 10.1016/j.vaccine.2010.03.033
DO - 10.1016/j.vaccine.2010.03.033
M3 - Article
VL - 28
SP - 3793
EP - 3800
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 22
ER -